Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 19/20 | 0.55 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | HTR2B | P41595 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20315440 | 0.92 | OPRL1 (0.49) | OPRL1HTR2AHTR2CSLC6A4HTR2B | |
| SCHEMBL4689150 | 0.92 | OPRL1 (0.49) | OPRL1HTR2AHTR2CSLC6A4HTR2B | |
| SCHEMBL505182 | 0.91 | OPRL1 (0.49) | OPRL1HTR2AHTR2CSLC6A4HTR2B | |
| SCHEMBL24736536 | 0.90 | OPRL1 (0.48) | OPRL1HTR2AHTR2CSLC6A4HTR2B | |
| SCHEMBL28710456 | 0.88 | OPRL1 (0.50) | OPRL1HTR2AHTR2CSLC6A4HTR2B | |
| SCHEMBL3386544 | 0.87 | SLC6A2 (0.52) | OPRL1SLC6A4 | |
| Hydrochloric Acid SCHEMBL4883036 | 0.85 | SLC6A4 (0.51) | OPRL1HTR2AHTR2CSLC6A4HTR2B | |
| SCHEMBL505573 | 0.85 | OPRL1 (0.48) | OPRL1HTR2AHTR2CSLC6A4HTR2B | |
| Bicarbonate SCHEMBL17644401 | 0.84 | OPRL1 (0.51) | OPRL1 | |
| SCHEMBL4972924 | 0.84 | OPRL1 (0.51) | OPRL1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234925-A1 | GPR52 MODULATORS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2016026830-A1 | NOVEL FUNGICIDAL PYRAZOLE DERIVATIVES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234925-A1 | GPR52 MODULATORS AND METHODS OF USE | GPR52, GPR68, GPR35 | OPRL1 47/4885HTR2A 78/4885HTR2C 171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.